Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7

키워드

참고문헌 (99)

1. Chen DS, "Oncology meets immuno-logy : the cancer-immunity cycle", Immunity, 39, pp.1~10 (2013)
2. Fridman WH, "The immune contexture in human tumours : impact on clini-cal outcome", Nat Rev Cancer, 12, pp.298~306 (2012)
3. Menetrier-Caux C, "Lymphopenia in cancer patients and its effects on response to immunotherapy : an opportunity for combina-tion with cytokines?", J Immunother Cancer, 7, pp.85~ (2019)
4. Leonard WJ, "The gammac family of cytokines : basic biology to therapeutic ramifications", Immunity, 50, pp.832~850 (2019)
5. Morgan DA, "Selective in vitro growth of T lymphocytes from normal human bone marrows", Science, 193, pp.1007~1008 (1976)
6. Boyman O, "The role of interleukin-2during homeostasis and activation of the immune system", Nat Rev Immunol, 12, pp.180~190 (2012)
7. Wang X, "Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors", Science, 310, pp.1159~1163 (2005)
8. Zhang X, "Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15", Immunity, 8, pp.591~599 (1998)
9. Boyman O, "Selective stimulation of T cell subsets with antibody-cytokine immune complexes", Science, 311, pp.1924~1927 (2006)
10. Sakaguchi S, "Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of im-mune responses", Annu Rev Immunol, 22, pp.531~562 (2004)
11. Liao W, "Modu-lation of cytokine receptors by IL-2 broadly regulates differ-entiation into helper T cell lineages", Nat Immunol, 12, pp.551~559 (2011)
12. Yang XP, "Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5", Nat Immunol, 12, pp.247~254 (2011)
13. Liao W, "Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression", Proc Natl Acad Sci U S A, 111, pp.3508~3513 (2014)
14. Laurence A, "Interleukin-2signaling via STAT5 constrains T helper 17 cell generation", Immunity, 26, pp.371~381 (2007)
15. Ballesteros-Tato A, "Interleukin-2inhibits germinal center formation by limiting T follicular helper cell differentiation", Immunity, 36, pp.847~856 (2012)
16. Sadlack B, "Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells", Eur J Immunol, 25, pp.3053~3059 (1995)
17. Willerford DM, "Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compart-ment", Immunity, 3, pp.521~530 (1995)
18. Suzuki H, "Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta", Science, 268, pp.1472~1476 (1995)
19. Almeida AR, "Homeostasis of peripheral CD4+ T cells : IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers", J Immunol, 169, pp.4850~4860 (2002)
20. Malek TR, "CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant func-tion of IL-2", Immunity, 17, pp.167~178 (2002)
21. Fontenot JD, "A function for interleukin 2 in Foxp3-expressing regulatory T cells", Nat Immunol, 6, pp.1142~1151 (2005)
22. Kalia V, "Prolonged interleukin-2Ralpha expres-sion on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo", Immunity, 32, pp.91~103 (2010)
23. Pipkin ME, "Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells", Immunity, 32, pp.79~90 (2010)
24. Lenardo M, "Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment", Annu Rev Immunol, 17, pp.221~253 (1999)
25. Rosenberg SA, "Observa-tions on the systemic administration of autologous lympho-kine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer", N Engl J Med, 313, pp.1485~1492 (1985)
26. Rosenberg SA, "Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients", Ann Surg, 210, pp.474~485 (1989)
27. Rosenberg SA, "Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2", JAMA, 271, pp.907~913 (1994)
28. Fyfe G, "Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy", J Clin Oncol, 13, pp.688~696 (1995)
29. Atkins MB, "High-dose recombinant interleukin 2 therapy for patients with meta-static melanoma : analysis of 270 patients treated between 1985 and 1993", J Clin Oncol, 17, pp.2105~2116 (1999)
30. Caligiuri MA, "Selec-tive modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2", J Clin Invest, 91, pp.123~132 (1993)
31. Caligiuri MA, "Extended continuous infusion low-dose recombinant interleukin-2in advanced cancer : prolonged immunomodulation without significant toxicity", J Clin Oncol, 9, pp.2110~2119 (1991)
32. Soiffer RJ, "Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and inter-mittent bolus administration of interleukin 2", Clin Cancer Res, 2, pp.493~499 (1996)
33. Fehniger TA, "Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy", J Clin Invest, 106, pp.117~124 (2000)
34. Wrangle JM, "IL-2 and beyond in cancer immunotherapy", J Interferon Cytokine Res, 38, pp.45~68 (2018)
35. Krieg C, "Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells", Proc Natl Acad Sci U S A, 107, pp.11906~11911 (2010)
36. Sim GC, "IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients", J Clin Invest, 124, pp.99~110 (2014)
37. Levin AM, "Exploiting a natural conformational switch to engineer an interleukin-2‘superkine’", Nature, 484, pp.529~533 (2012)
38. Ardolino M, "Cytokine therapy reverses NK cell anergy in MHC-deficient tumors", J Clin Invest, 124, pp.4781~4794 (2014)
39. Mortara L, "Anti-cancer therapies employing IL-2cytokine tumor targeting : contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy", Front Immunol, 9, pp.2905~ (2018)
40. Ishihara J, "Targeted antibody and cytokine cancer immunotherapies through collagen affinity", Sci Transl Med, 11, pp.eaau3259~ (2019)
41. Mostbock S, "Cytokine", Antibody complexes : an emerging class of immunostimulants, 2009, pp.15, 809~825
42. Kamimura D, "IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb", J Immunol, 177, pp.306~314 (2006)
43. Jin GH, "Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation", Int Immunol, 20, pp.783~789 (2008)
44. Roopenian DC, "FcRn : the neonatal Fc receptor comes of age", Nat Rev Immunol, 7, pp.715~725 (2007)
45. Zhu EF, "Synergistic innate and adaptive immune response to combination immunothe-rapy with anti-tumor antigen antibodies and extended serum half-life IL-2", Cancer Cell, 27, pp.489~501 (2015)
46. Sun Z, "A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltra-ting CD8(+)T-cell response and effective tumor control", Nat Commun, 10, pp.3874~ (2019)
47. Yang JC, "The use of polyehylene glycol-modified interleukin-2(PEG-IL-2)in the treatment of patients with metastatic renal cell carcinoma and melanoma", Cancer, 76, pp.687~694 (1995)
48. Charych DH, "NKTR214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor Models", Clin Cancer Res, 22, pp.680~690 (2016)
49. Sharma M, "Bempegaldes-leukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy", Nat Commun, 11, pp.661~ (2020)
50. Mackall CL, "Harnessing the biology of IL-7 for therapeutic application", Nat Rev Immunol, 11, pp.330~342 (2011)
51. Link A, "Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells", Nat Immunol, 8, pp.1255~1265 (2007)
52. Grace Yoonhee Kim, "Seeing is Believing: Illuminating the Source of In Vivo Interleukin-7", Immune Network, 11(1), pp.1~10 (2011), 대한면역학회
53. Guimond M, "Inter-leukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells", Nat Immunol, 10, pp.149~157 (2009)
54. Al-Shami A, "A role for thymic stromal lymphopoietin in CD4(+)T cell development", J Exp Med, 200, pp.159~168 (2004)
55. Peschon JJ, "Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice", J Exp Med, 180, pp.1955~1960 (1994)
56. von Freeden-Jeffry U, "Lymphopenia in inter-leukin(IL)-7 gene-deleted mice identifies IL-7 as a nonre-dundant cytokine", J Exp Med, 181, pp.1519~1526 (1995)
57. Clark MR, "Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling", Nat Rev Immunol, 14, pp.69~80 (2014)
58. Puel A, "Defective IL7R expression in T(-)B(+)NK(+)severe combined immunodeficiency", Nat Genet, 20, pp.394~397 (1998)
59. Mazzucchelli R, "Interleukin-7 recep-tor expression : intelligent design", Nat Rev Immunol, 7, pp.144~154 (2007)
60. Kondo M, "Bcl-2 rescues T lymphopoiesis, but not B or NK cell development, in common gamma chain-deficient mice", Immunity, 7, pp.155~162 (1997)
61. Akashi K, "Bcl-2 rescues T lymphopoiesis in inter-leukin-7 receptor-deficient mice", Cell, 89, pp.1033~1041 (1997)
62. Maraskovsky E, "Bcl-2 can rescue T lym-phocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1(-", -)mice, 1997, pp.89, 1011~1019
63. Pellegrini M, "Loss of Bim increases T cell produc-tion and function in interleukin 7 receptor-deficient mice", J Exp Med, 200, pp.1189~1195 (2004)
64. Khaled AR, "Bax deficiency partially corrects interleukin-7 receptor alpha deficiency", Immunity, 17, pp.561~573 (2002)
65. Boudil A, "IL-7 coordinates proliferation, differentiation and Tcra recombination during thymocyte beta-selection", Nat Immunol, 16, pp.397~405 (2015)
66. Moore TA, "Inhibition of gamma delta T cell development and early thymocyte maturation in IL-7-", -mice, 1996, pp.157, 2366~2373
67. Shitara S, "IL-7 produced by thymic epithelial cells plays a major role in the development of thymocytes and TCRgammadelta+ intraepithelial lymphocytes", J Immunol, 190, pp.6173~6179 (2013)
68. Vosshenrich CA, "A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127", Nat Immunol, 7, pp.1217~1224 (2006)
69. Vogt TK, "Novel function for interleukin-7 in dendritic cell develop-ment", Blood, 113, pp.3961~3968 (2009)
70. Soares MV, "IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire", J Immunol, 161, pp.5909~5917 (1998)
71. Swainson L, "IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway", Blood, 109, pp.1034~1042 (2007)
72. Ernst B, "The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery", Immunity, 11, pp.173~181 (1999)
73. Goldrath AW, "Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts", Immunity, 11, pp.183~190 (1999)
74. Surh CD, "Homeostasis of naive and memory T cells", Immunity, 29, pp.848~862 (2008)
75. Surh CD, "Regulation of mature T cell homeostasis", Semin Immunol, 17, pp.183~191 (2005)
76. Hennion-Tscheltzoff O, "TCR triggering modulates the responsiveness and homeostatic proliferation of CD4+ thymic emigrants to IL-7 therapy", Blood, 121, pp.4684~4693 (2013)
77. Park JH, "‘Coreceptor tuning’ : cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR", Nat Immunol, 8, pp.1049~1059 (2007)
78. Seddiki N, "Ex-pression of interleukin(IL)-2 and IL-7 receptors discrimi-nates between human regulatory and activated T cells", J Exp Med, 203, pp.1693~1700 (2006)
79. Liu W, "CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells", J Exp Med, 203, pp.1701~1711 (2006)
80. Barata JT, "Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells", J Exp Med, 200, pp.659~669 (2004)
81. Wofford JA, "IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival", Blood, 111, pp.2101~2111 (2008)
82. Cui GL, "IL-7-induced glycerol transport and TAG synthesis promotes memory CD8(+)T cell longevity", Cell, 161, pp.750~761 (2015)
83. Kimura MY, "IL-7signaling must be intermittent, not continuous, during CD8(+)T cell homeostasis to promote cell survival instead of cell death", Nat Immunol, 14, pp.143~151 (2013)
84. Rosenberg SA, "IL-7administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells", J Immunother, 29, pp.313~319 (2006)
85. Sportes C, "Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets", J Exp Med, 205, pp.1701~1714 (2008)
86. Tredan O, "ELYPSE-7 : a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients", Ann Oncol, 26, pp.1353~1362 (2015)
87. Merchant MS, "Adjuvant immunotherapy to improve outcome in high-risk pe-diatric sarcomas", Clin Cancer Res, 22, pp.3182~3191 (2016)
88. Reimers MA, "Immunotherapy in metastatic castration-resistant prostate cancer : past and future strategies for optimization", Curr Urol Rep, 20, pp.64~ (2019)
89. Sportes C, "Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy", Clin Cancer Res, 16, pp.727~735 (2010)
90. Miller PW, "Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication", Hum Gene Ther, 11, pp.53~65 (2000)
91. Li B, "Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell im-munotherapy", Clin Immunol, 123, pp.155~165 (2007)
92. Pellegrini M, "Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies", Nat Med, 15, pp.528~536 (2009)
93. Andersson A, "Role of CXCR3 ligands in IL-7", IL-7R alpha-Fc-mediated antitumor activity in lung cancer, 2011, pp.17, 3660~3672
94. Boyman O, "IL-7", anti-IL-7 mAb complexes restore T cell develop-ment and induce homeostatic T cell expansion without lymphopenia, 2008, pp.180, 7265~7275
95. Martin CE, "IL-7", anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R, 2013, pp.121, 4484~4492
96. Nam HJ, "Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant", Eur J Immunol, 40, pp.351~358 (2010)
97. Lee SW, "hIL-7-hyFc, a longacting IL-7, increased absolute lymphocyte count in healthy subjects", Clin Transl Sci, 13, pp.1161~1169 (2020)
98. Choi YW, "Intravaginal administration of Fc-fused IL7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells", Clin Cancer Res, 22, pp.5898~5908 (2016)
99. Kim JH, "Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy", Clin Transl Immunology, 9, pp.e1168~ (2020)

관련 논문AI추천